M Health Fairview St. John's Hospital

Maplewood, Minnesota 55109

6 studies enrolling now · 13 studies all time

What they study most

Atrial Fibrillation, Bleeding, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Cervical Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms, Heart Failure, Intracerebral Hemorrhage, Moderate Aortic Valve Stenosis, Non-Small Cell Lung Cancer

Studies at this site

• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer — Recruiting now
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. — Recruiting now
• Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer — Recruiting now
• The CONFORM Pivotal Trial — Recruiting now
• Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study — Recruiting now
• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 — Recruiting now
• LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. — Running, not enrolling
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 — Running, not enrolling
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 — Running, not enrolling
• SIMPLAAFY Clinical Trial — Running, not enrolling
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial — Running, not enrolling
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling